Compare ClearPoint Neuro Inc (CLPT) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Oxford Lane Capital Corp — how do they compare? ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M), while Oxford Lane Capital Corp trades at $9.16 (market cap $891.54M). The key difference: Oxford Lane Capital Corp is the larger of the two by market cap, and Oxford Lane Capital Corp pays a 26.29% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | OXLC | |
|---|---|---|
Market Cap | $478.63M | $891.54M |
Sector | Health | Financials |
52-Week High | $29.60 | $20.80 |
52-Week Low | $8.66 | $8.15 |
Enterprise Value | $506.63M | — |
Dividend Yield | — | 26.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
OXLC trades at $9.19, up 0.66% today, with a mixed technical outlook showing bullish moving averages but overbought RSI levels. The company reported a net income margin of 100.85% for 2025, but earnings misses and a sharp revenue decline to -$580M in 2026 highlight volatility. Recent news includes dividend declarations and a net asset value update from Oxford Lane Capital on June 15, 2026.
Outlook is cautious due to inconsistent earnings and high yield sustainability concerns. Risks include NAV decay and competitive pressures, while opportunities lie in dividend income. Analyst consensus is split, with 50% buy ratings but significant sell coverage citing fund performance issues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
